🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For those undaunted by drugging the currently undruggable: we're excited to announce the TBXT Challenge, a drug discovery competition for the cancer target TBXT (brachyury) with $500K+ in prizes: tbxtchallenge.org

Interesting finding and possibly relevant to chordoma given frequent 9p21 loss.

I’m delighted to share that Thomas Löhr, Gogs, and I are launching Bind Research, a UK-based not-for-profit research startup to deliver publicly–available tools and datasets to make intrinsically disordered proteins druggable. 🍝 💊🧲 💻 🦠

We’re excited about the launch of Bind Research and look forward to working together to unlock new ways to drug TBXT

John Henry Owen and the Michigan Otolaryngology University of Michigan Head & Neck Oncology team are unsung heroes of chordoma research for developing and willingly sharing a number of the workhorse cell lines we and other labs use daily. We’re deeply grateful for their tireless and meticulous efforts over many years!

Protein Data Bank Zenodo So others don't have to reinvent the wheel, we've developed and offer capabilities to support TBXT drug discovery including purified protein production, SPR and various functional assays. For more info see below or get in touch: [email protected] chordomafoundation.org/researchers/tb…

Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy nature.com/articles/s4146…

TBXT CHALLENGE: DRUG THE UNDRUGGABLE Compete for $500K+ in prizes for breakthroughs in developing drugs for the cancer-associated transcription factor TBXT, also known as Brachyury. More information here: tbxtchallenge.org

We're happy to share that Pyxis Oncology's Phase 1 trial of PYX-201 (Micvotabart pelidotinaka “MICVO”) has opened to patients with sarcomas, including chordoma: clinicaltrials.gov/study/NCT05720… This opportunity came about in part from a discovery made using tumor tissue from our Biobank,

Fascinating: the chordoma associated TBXT SNP rs2305089 also causes a predisposition to benign notochordal cell tumors—with 15% of chordoma patients harboring a BNCT and 6% harboring more than one. Great work from Inga Usher Lucia Cottone UCL Cancer Institute! …thsocjournals.onlinelibrary.wiley.com/doi/10.1002/pa…

Happy the TBXT Challenge is inspiring new approaches to take on this important target and appreciative of everyone making that happen!

🗣️ We're hiring a Director of Preclinical Research! This is an exciting opportunity for an oncology R&D leader to make a tangible impact in the lives of patients in urgent need of new treatment options. More info: chordoma.org/team/careers/